17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto
Posted at 12:50h
in
Important safety information on the treatment of patients with antiphospholipid syndrome (APS) and the use of rivaroxaban (Xarelto®) Possible increased risk for recurrent thrombotic events
2019 Aug
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
15/08/2019
File Type:
pdf
Category:
Communication To Health Care Professionals